Phase I, Single-centre, Open-label Study to Evaluate the Pharmacokinetics of ALX-0171, Administered by Oral Inhalation or Intravenously, in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2014
At a glance
- Drugs ALX 0171 (Primary) ; ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Ablynx
- 16 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Jul 2013 The results of this study are expected during the first half of 2014, according to an Ablynx media release.